64779-08-4

Usage

InChI:InChI=1/C16H22O3/c1-2-3-4-5-6-13-7-9-14(10-8-13)15(17)11-12-16(18)19/h7-10H,2-6,11-12H2,1H3,(H,18,19)

Upstream product

• 108-30-5 succinic acid anhydride 
• 1077-16-3 hexylbenzene 
• 7446-70-0 aluminium trichloride 
• 630-20-6 1,1,1,2-tetrachoroethane 

Downstream Products

• 147427-38-1 4-(4-hexyl-phenyl)-butyric acid 
• 183129-83-1 4-(4-Hexylphenyl)butanol 
• 183129-87-5 4-(4-Hexyl-phenyl)-butyraldehyde 
• 183129-95-5 {2-Amino-5-[2-(4-hexyl-phenyl)-ethyl]-thiophen-3-yl}-(2-chloro-phenyl)-methanone 
• 183130-02-1 2-Chloro-N-{3-(2-chloro-benzoyl)-5-[2-(4-hexyl-phenyl)-ethyl]-thiophen-2-yl}-acetamide 
• 1027263-85-9 N-{3-(2-Chloro-benzoyl)-5-[2-(4-hexyl-phenyl)-ethyl]-thiophen-2-yl}-2-iodo-acetamide 
• 183130-13-4 2-Amino-N-{3-(2-chloro-benzoyl)-5-[2-(4-hexyl-phenyl)-ethyl]-thiophen-2-yl}-acetamide 
• 117280-35-0 5-(2-chlorophenyl)-7-[2-(4-n-hexylphenyl)ethyl]-1,3-dihydro-2H-thieno[2,3-e]-1,4-diazepin-2-one 
• 117280-36-1 5-(2-chlorophenyl)-7-[2-(4-n-hexylphenyl)ethyl]-1,3-dihydro-2H-thieno[2,3-e]-1,4-diazepine-2-thione 
• 117280-37-2 [5-(2-Chloro-phenyl)-7-[2-(4-hexyl-phenyl)-ethyl]-1,3-dihydro-thieno[2,3-e][1,4]diazepin-(2Z)-ylidene]-hydrazine 
• 145772-45-8 4-(4-hexyl-cyclohexyl)-butyric acid 

Relevant academic research and scientific papers

Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: Pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system

A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (±)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]- 6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.